Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2005
03/31/2005DE10340845A1 Pharmazeutisches Kombinationspräparat, enthaltend Glycyrrhizinsäure, Zink und eine Verbindung, die eine Thiolgruppe oder eine zu dieser metabolisierbare Gruppe enthält A pharmaceutical combination preparation containing glycyrrhizic acid, zinc and a compound containing a thiol group or a metabolizable to this group
03/31/2005DE10340740A1 Physiologisch aktive Zusammensetzung auf Phosphatidylserin-Basis Physiologically active composition phosphatidylserine base
03/31/2005DE10331202A1 Verwendung von Molkenpermeat zur Behandlung des Metabolischen Syndroms Use of whey permeate for the treatment of metabolic syndrome
03/31/2005DE10158057B4 Arzneimittel für die Behandlung von infektiösen Erkrankungen, insbesondere Tuberkulose und Malaria Drugs for the treatment of infectious diseases, especially malaria and tuberculosis
03/31/2005CA2808646A1 Thalidomide analogs
03/31/2005CA2805552A1 Thyroid hormone analogs and methods of use in angiogenesis
03/31/2005CA2676567A1 Methods for treatment of hiv or malaria using combinations of chloroquine and protease inhibitors
03/31/2005CA2551037A1 Novel piperidine derivative
03/31/2005CA2540407A1 Compositions and methods using same for treating amyloid-associated diseases
03/31/2005CA2540329A1 2-pyridinone derivatives, having hiv inhibiting properties
03/31/2005CA2540133A1 Drugs for treating cancer
03/31/2005CA2540129A1 Pharmaceutical delivery system
03/31/2005CA2540105A1 Enteric soft gelatin capsule containing esomeprazole and method of preparation
03/31/2005CA2539848A1 Acyloxymethylcarbamate prodrugs of oxazolidinones
03/31/2005CA2539842A1 Amidines and derivatives thereof and pharmaceutical compositions containing them
03/31/2005CA2539799A1 5-aminosalicylic acid solid preparation improved in discoloration and method of storing the same
03/31/2005CA2539766A1 Benzimidazole derivates: preparation and pharmaceutical applications
03/31/2005CA2539751A1 Bone cement compositions having fiber-reinforcement and/or increased flowability
03/31/2005CA2539741A1 Prevention and treatment of inflammation-induced and/or immune-mediated bone loss
03/31/2005CA2539661A1 Steroidal quinols and their use for estrogen replacement therapy
03/31/2005CA2539644A1 Hair restorer
03/31/2005CA2539590A1 Polyether brevetoxin derivatives as a treatment for cystic fibrosis, mucociliary dysfunction, and pulmonary diseases
03/31/2005CA2539588A1 Fused pentacyclic polyethers
03/31/2005CA2539566A1 Benzimidazolone and quinazolinone derivatives as agonists on human orl1 receptors
03/31/2005CA2539554A1 Phenylacetic acid derivative, process for producing the same, and use
03/31/2005CA2539548A1 Novel heterocyclic compounds as hsp90-inhibitors
03/31/2005CA2539377A1 Combinations of alpha-2-delta ligands and acetylcholinesterase inhibitors
03/31/2005CA2539364A1 Carbohydrate composition and its use for the preparation of a medicament for treating or preventing pulmonary inflammation or acute respiration distress syndrome
03/31/2005CA2539361A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and an estrogen agonist/antagonist
03/31/2005CA2539359A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
03/31/2005CA2539358A1 2-alkylidene-19-nor-vitamin d derivatives for the treatment of osteopenia or male osteoporosis
03/31/2005CA2539357A1 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
03/31/2005CA2539324A1 Transscleral delivery
03/31/2005CA2539320A1 Use of chk1 inhibitors to control cell proliferation
03/31/2005CA2539314A1 Thiazolopyridine derivatives as adenosine receptor ligands
03/31/2005CA2539309A1 Dimethoxy docetaxel acetone solvate et method for the preparation thereof
03/31/2005CA2539306A1 Haloalkyl containing compounds as cysteine protease inhibitors
03/31/2005CA2539301A1 Abiotic heparin antagonists
03/31/2005CA2539288A1 Thyroid hormone analogs and methods of use
03/31/2005CA2539276A1 Methods of preventing or treating recurrence of myocardial infarction
03/31/2005CA2539182A1 Chronotherapeutic dosage forms
03/31/2005CA2539181A1 Modulation of eif4e expression
03/31/2005CA2539165A1 Cinnamoyl compound and use of the same
03/31/2005CA2539162A1 Cinnamoyl derivatives and use thereof
03/31/2005CA2539159A1 Aminoalkylamide substituted cyclohexyl derivatives
03/31/2005CA2539021A1 Combination approaches for generating immune responses
03/31/2005CA2538993A1 2-alkylidene-19-nor-vitamin d derivatives for the treatment of frailty, muscle damage or sarcopenia
03/31/2005CA2538991A1 Treatment of severe distal colitis
03/31/2005CA2538960A1 Cinnamoyl compound and use of the same
03/31/2005CA2538874A1 Benzopyranone compounds, compositions thereof, and methods of treatment therewith
03/31/2005CA2538864A1 Thalidomide analogs as tnf-alpha modulators
03/31/2005CA2538857A1 Synthesis and manufacture of pentostatin and its precursors, analogs and derivatives
03/31/2005CA2538855A1 1,4-disubstituted isoquinilone derivatives as raf-kinase inhibitors useful for the treatment of proliferative diseases
03/31/2005CA2538846A1 Enhanced method of treatment of growth disorders
03/31/2005CA2538802A1 Treating or preventing restless legs syndrome using prodrugs of gaba analogs
03/31/2005CA2538789A1 Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acety lcholine receptors
03/31/2005CA2538760A1 Human .beta.-defensin secretion promoter
03/31/2005CA2538756A1 Polymorphic forms of a known antihyperlipemic agent
03/31/2005CA2538729A1 Compound and method for treating androgen-independent prostate cancer
03/31/2005CA2538591A1 Synthesis of quinoline 5-carboxamides useful for the preparation of pde iv inhibitors
03/31/2005CA2538590A1 Novel gamma secretase inhibitors
03/31/2005CA2538570A1 Combinations of drugs for the treatment of neoplasms
03/31/2005CA2538527A1 Fluid medication delivery device
03/31/2005CA2538523A1 Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
03/31/2005CA2538454A1 Derivatives of n-(1h-indazolyl)- and n-(1h-indolyl)-urea as well as related compounds as modulators of the vanilloid-1 receptor (vr1) for the treatment of pain
03/31/2005CA2538381A1 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (gsk-3)
03/31/2005CA2538366A1 Concurrent drugs
03/31/2005CA2538291A1 Substituted sulfonamides
03/31/2005CA2538252A1 4'-thionucleosides and oligomeric compounds
03/31/2005CA2537991A1 Combination of a vegf receptor inhibitor with a chemotherapeutic agent
03/31/2005CA2537989A1 Methods and reagents for the treatment of immunoinflammatory disorders
03/31/2005CA2537916A1 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
03/31/2005CA2537731A1 Compositions useful as inhibitors of protein kinases
03/31/2005CA2537325A1 Aza-quinolinol phosphonate integrase inhibitor compounds
03/31/2005CA2537094A1 Novel adenosine a3 receptor agonists
03/31/2005CA2537080A1 Liquid formulations for the prevention and treatment of mucosal diseases and disorders
03/31/2005CA2536636A1 Cephem compounds
03/31/2005CA2536609A1 Anhydrous topical formulation for polyphenols
03/31/2005CA2535645A1 Therapeutic immunization of hiv-infected individuals
03/31/2005CA2528095A1 Compositions for inactivating pathogenic microorganisms, methods of making the compositions, and methods of use thereof
03/31/2005CA2528009A1 Control of protozoa and protozoan cysts that harbor legionella
03/31/2005CA2526862A1 Methods of diagnosing, prognosing and treating breast cancer
03/30/2005EP1518858A1 Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments
03/30/2005EP1518855A1 Diaminopyrimidinecarboxa mide derivative
03/30/2005EP1518854A1 Substituted 06- benzylguanines and 7- or 9- substituted 8-aza-06-benzylguanines
03/30/2005EP1518836A2 Substrate with photocatalytic coating
03/30/2005EP1518827A1 Cristalline material IM-12 and process for its manufacture
03/30/2005EP1518562A2 Dopamine transporter imaging agents
03/30/2005EP1518561A2 Dopamine transporter imaging agents
03/30/2005EP1518560A1 Use of a gas for the manufacture of a diagnosing agent for diagnosing coronary perfusion
03/30/2005EP1518559A1 Use of a gas for the manufacture of a monitoring agent for diagnosing passage through the intestinal tract or exocrine function of the pancreas
03/30/2005EP1518556A1 Therapeutic agent for brain hemorrhage
03/30/2005EP1518555A1 Analgesic combination of opioid analgesic and cyclooxygenase-2 inhibitor
03/30/2005EP1518554A1 Pharmaceutical composition for the treatment of hyperhomocysteinemia
03/30/2005EP1518553A2 Use of nitrate ester compounds for treating pain or providing analgesia
03/30/2005EP1518551A1 Solid dosage form comprising caffeine
03/30/2005EP1518549A1 A pellet comprising a local anesthetic agent and a radiopaque material
03/30/2005EP1518517A2 Drug-delivery endovascular stent and method for treating restenosis
03/30/2005EP1517989A2 Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
03/30/2005EP1517924A1 Process for the manufacture of n-acyl-(epi)k5-amine-o-sulfate-derivatives and products thus obtained
1 ... 4737 4738 4739 4740 4741 4742 4743 4744 4745 4746 4747 4748 4749 4750 4751 4752 4753 4754 4755 4756 4757 ... 7860